This 7NEWS article reports on a new pancreatic cancer blood test being developed by BCAL Diagnostics that uses similar detection principles to pregnancy tests. The test is designed to identify pancreatic cancer before symptoms appear, potentially allowing earlier intervention and better patient outcomes.
The article features comments from advocates and patients affected by pancreatic cancer, highlighting the devastating impact of late-stage diagnosis. It explains that pancreatic cancer is often difficult to detect because symptoms appear late and are frequently vague or mistaken for less serious conditions.
Dr Chris Baldwin from BCAL Diagnostics explains that the test analyses biomarkers in blood associated with cancer activity, enabling clinicians to identify disease before patients become symptomatic. Trial results reportedly showed the test could detect pancreatic cancer even in patients without symptoms.
The article states that early detection is critical because treatment is far more effective before the cancer spreads. It also highlights the emotional significance of the technology for families with inherited pancreatic cancer risk and notes that the test currently costs around $149 and is not yet covered by Medicare.
